A new method of vaccine creation for Chikungunya virus (CHIKV) using a technique called large scale random codon re-encoding was developed by researchers. This method has helped them modify nucleic acid composition of the virus without changing encoded viral proteins.
Using this approach, a group from the UMR_D 190, Emerging viruses Department in Marseille, France in collaboration with the University of Sydney, Australia, showed that the engineered viruses exhibit a stable phenotype with a significantly decreased viral fitness (i.e., replication capacity), making it a new vaccine candidate for the emerging viral disease.
Chikungunya
Chikungunya is a viral disease spread by mosquito bites; it causes fever, severe joint pain and rash on the body. Chikungunya occurs in Africa, Asia and the Indian sub continent.
Advertisement
When the large-scale codon re-encoding method was applied by Antoine Nougairede and his colleagues to poliovirus and Influenza A virus, it resulted in a live but attenuated virus that had significant reduction of viral fitness.
This study demonstrates that a random approach reduced the replicative fitness of CHIKV in both primate and arthropod cells.
The strategy also prevented the reversion of the attenuated phenotype by mutation or recombination, thus reducing the possibility that the newly created virus strain could evolve back to the pathogenic version.
The findings suggest that large-scale codon re-encoding can provide a strong basis for the rapid design of next-generation viral vaccines against emerging viral pathogens, as soon as their genome sequence has been determined.
It represents another route to vaccine development as it intrinsically alleviates the likelihood of novel pathogenic properties of the designed live vaccine, and allows modulation of the amount of reduced fitness by altering the terms and degree of the genetic re-encoding.
Thus, this strategy potentially allows for the generic development of live attenuated vaccines against many new viral pathogens, with reduced costs and the potential single dose induction of long-term immunity.
This report has been published in the Open Access journal, PLOS Pathogens.
Source: ANI
The strategy also prevented the reversion of the attenuated phenotype by mutation or recombination, thus reducing the possibility that the newly created virus strain could evolve back to the pathogenic version.
Advertisement
The findings suggest that large-scale codon re-encoding can provide a strong basis for the rapid design of next-generation viral vaccines against emerging viral pathogens, as soon as their genome sequence has been determined.
It represents another route to vaccine development as it intrinsically alleviates the likelihood of novel pathogenic properties of the designed live vaccine, and allows modulation of the amount of reduced fitness by altering the terms and degree of the genetic re-encoding.
Thus, this strategy potentially allows for the generic development of live attenuated vaccines against many new viral pathogens, with reduced costs and the potential single dose induction of long-term immunity.
This report has been published in the Open Access journal, PLOS Pathogens.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Chikungunya News
Researchers evaluated whether systemic anticancer therapies and comorbidities were associated with COVID-19 mortality among adults with cancer and COVID-19.
A multi-country study led by IVI in partnership with BBIL, funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology, India starts clinical trial on chikungunya vaccine.
Combination of zika virus and chikungunya virus is found to trigger stroke. Stroke following zika and chikungunya virus can be deadly and also result in death.
Healthy gut bacteria reduces the severity of mosquito-borne viral infections like chikungunya, by regulating inflammation and the body's response to infection. They help reduce the community spread of infection by disrupting the virus transmission from one person to another via mosquitoes.
Structure of chikungunya virus promises to accelerate efforts to design drugs and vaccines to prevent or treat arthritis caused by chikungunya or related viruses.
